Overview

There is a tremendous amount of mechanistic overlap between targeted cancer therapy and cardiovascular tissues. Important drugs that may be active on cancer are increasingly likely to have significant collateral effects on cardiovascular structures. Understanding the underlying mechanisms and how to detect these problems early and manage them effectively can allow a critical drug for cancer efficacy to continue to develop as a clinical therapy. Additionally, tailoring the pharmacology of a potential cancer therapeutic based on known mechanistic insights is an essential area of preclinical development. Furthermore, enhancing interactions between cardiology and oncology at all levels of clinical trials allows for optimal patient outcomes.

Key Topics

- Best methods of cardiotoxicity detection during early phase clinical trials
- Best management approaches to protecting cardiac tissues during aggressive cancer therapy
- Known and theorised mechanistic actions of developing cancer therapy to allow cardioprotection
- Effective communication between drug developers and prescribers
- Optimal patient care between cardiology and oncology

Who Will Attend

- Cardiology, oncology and primary care physicians, nurse practitioners, and other allied providers
- Drug development and clinical research managers and associates
- Pharmacovigilance, drug safety and drug surveillance personnel
- Pharmaceutical physicians and medical directors
- Safety pharmacology and non-clinical scientists
- Clinical pharmacology scientists
- Regulatory affairs officers
- Biostatisticians
- Data managers
- Outsourcing and marketing managers

The audience will include clinical research and industry experts including drug development scientists, regulatory officials and academicians managing patients undergoing cancer therapy.

For more information please contact Sharon.Evans@diaeurope.org | +41 61 225 51 44

Exhibition Opportunities Available!

Showcase your product or service to a truly global audience of qualified professionals, from entry level to expert, in the pharmaceutical, biotechnology, devices and related healthcare industries, government, academia and healthcare delivery.

For more information on exhibiting space and facilities, please contact Roxann Schumacher at DIA on +41 61 225 51 38 or email: roxann.schumacher@diaeurope.org

Programme Co-Chairs:

Boaz Mendzelevski
Vice President of Cardiology, Bioclinica Inc, UK

Daniel J. Lenihan
President, International CardiOncology Society North America (ICOSNA), Director of Cardiovascular Clinical Research Programs, Vanderbilt University, Vanderbilt University, USA

Programme Committee

Giuseppe Curigliano, MD
President, International CardiOncology Society (ICOS) Europe, Senior Deputy Director, European Institute of Oncology, Italy

Krishna Prasad, MD
Group Manager (Interim) /Expert Assessor, MHRA; Consultant Cardiologist, St Thomas’ Hospital, UK

Continuing Education

DIA meetings are generally approved by the SwAPP (Swiss Association of Pharmaceutical Professionals), Commission for Professional Development (CPD) and SGPM (Swiss Society of Pharmaceutical Medicine) and will be honoured with credits for pharmaceutical medicine. All participants are eligible for these credits and certificates are available on request from the registration desk.
09 OCTOBER 2014

08:00 REGISTRATION AND WELCOME COFFEE

08:50 WELCOME AND OPENING COMMENTS
Boaz Mendzelevski, Vice President of Cardiology, Bioclinica Inc, UK

09:00 Session 1
PRECLINICAL MODELS FOR ENSURING CARDIAC SAFETY
Co-Moderators:
Boaz Mendzelevski, Vice President of Cardiology, Bioclinica Inc, UK
Krishna Prasad, MD
Group Manager (Interim) /Expert Assessor, MHRA; Consultant Cardiologist, St Thomas’ Hospital, UK

In this session we will describe the scope of toxicities and how these are documented.

Cardiac Safety During Cancer Therapy: Clinical relevance and the scope of the problem
Daniel J. Lenihan, President, International CardiOncology Society North America (ICOSNA), Director of Cardiovascular Clinical Research Programs, Vanderbilt University, Vanderbilt University, USA

Preclinical Monitoring and Safety: Receptor cross-targets in cancer and cardiac tissue
Speaker invited

How Do We Detect Anticipated and Unanticipated Cardiac Toxicities in Early Phase Studies?
Jakob Dupont, Vice President, Clinical Development; Oncomed, USA

Panel Discussion: All Speakers and Moderators

10:30 COFFEE BREAK

11:00 Session 2
DIRECT MYOCARDIAL TOXICITY, CARDIAC BIOMARKERS, AND DETECTING HEART FAILURE
Co-Moderators:
Alexander Lyon, Senior Lecturer and Consultant Cardiologist, Royal Brompton Hospital, London, UK
Daniela Cardinale, Vice-President, International CardiOncology Society (ICOS) Europe and Asia; Director, Cardio-Oncology Unit, European Institute of Oncology, Italy

In this session we will describe direct myocardial toxicity and detection in the clinical arena.

Cancer Drug Development: Many potential targets can have cardiotoxicity
Alexander Lyon, Senior Lecturer and Consultant Cardiologist, Royal Brompton Hospital, London, UK

Role of Troponin and Natriuretic Peptides in Predicting and Preventing Cardiac Events in Cancer Patients
Daniela Cardinale, Vice-President, International CardiOncology Society (ICOS) Europe and Asia; Director, Cardio-Oncology Unit, European Institute of Oncology, Italy

What Cut-Off for B-type Natriuretic Peptide (BNP) Should We Have to Identify Risk for Heart Failure?
Kenneth McDonald, Chronic Cardiovascular Disease Management Unit, St Vincent’s Healthcare Group, Ireland

Panel Discussion: All Speakers and Moderators

12:30 LUNCH

13:30 Session 3
CARDIAC SAFETY IMAGING IN CLINICAL RESEARCH
Co-Moderators:
Okan Ekinci, Global Director, Cardiology, Siemens Healthcare, Germany
Daniel Rodriguez Muñoz, Department of Cardiology, Ramón y Cajal University Hospital, Spain

In this session the latest considerations for clinical imaging and cardiac safety will be highlighted.

What are the Expectations for Optimal Echo Imaging?
Daniel Rodriguez Muñoz, Department of Cardiology, Ramón y Cajal University Hospital, Spain

How can MRI be Utilised Most Effectively?
Okan Ekinci, Global Director, Cardiology, Siemens Healthcare, Germany

Are Nuclear Techniques Really Obsolete?
Otto Lang, Department of Nuclear Medicine, Third Faculty of Medicine, Charles University, Czech Republic

Panel Discussion: All Speakers and Moderators

15:00 COFFEE BREAK

15:30 Session 4
CELLULAR SIGNALING AND LEFT VENTRICULAR DYSFUNCTION: TOXICITY MITIGATION OR THERAPEUTIC TREATMENT?
Co-Moderators:
Giuseppe Curigliano, President, International CardiOncology Society (ICOS) Europe, Senior Deputy Director, European Institute of Oncology, Italy
Susan Dent, President, International CardiOncology Society (ICOS) Canada, Medical Oncologist, Founder, Canadian Cardiac Oncology Network, Canada

In this session the concept of translational research informing clinical practice will be introduced.

How does Cardiotoxicity Affect our Cancer Treatment Choices?
Giuseppe Curigliano, President, International CardiOncology Society (ICOS) Europe, Senior Deputy Director, European Institute of Oncology, Italy

Neuregulin: A classic ligand for myocardial protection?
Tony Caggiano, Director of Translational Research, Acorda Therapeutics, USA

Cardioprotection: Do we target the myocardium or the patient?
Xavier Bosch, Hospital and Clinic, Barcelona, Spain

Panel Discussion: All Speakers and Moderators

Summary and Closing Comments
Giuseppe Curigliano, President, International CardiOncology Society (ICOS) Europe, Senior Deputy Director, European Institute of Oncology, Italy

17:40 DRINKS RECEPTION

18:30 END OF DAY ONE

DISCLOSURE
Unless otherwise disclosed, DIA Europe acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organisation they represent, or that of the DIA Europe. Speakers and agenda are subject to change without notice. Recording of any DIA Europe information in any type of media is prohibited without prior written consent from DIA Europe.
Roadmap for Approving Generic or Biosimilar Antibodies
Krishna Prasad, Group Manager (Interim) /Expert Assessor, MHRA; Consultant Cardiologist, St Thomas’ Hospital, UK

Panel Discussion: All Speakers and Moderators

15:30 COFFEE BREAK

16:00 Session 8
INTEGRATION AND COOPERATION-HOW DO WE ACHIEVE THIS?
Co-Moderators:
Susan Dent, President, International CardiOncology Society (ICOS) Canada, Medical Oncologist, Founder, Canadian Cardiac Oncology Network, Canada
Daniel J. Lenihan, President, International CardiOncology Society North America (ICOSNA), Director of Cardiovascular Clinical Research Programs, Vanderbilt University, Vanderbilt University, USA

In this session we will explore how to integrate cardiac safety into oncology research and practice.

How Do We Organise and Deliver on Cooperation among Disciplines
Speaker invited

Cardiac Safety Assessment in Oncology Drug Development: Regulatory Involvement in International Collaborative Activities
Colette Strnadova, Senior Scientific Advisor, Health Canada, Canada

How Do We Best Interact on Patient Care: An Oncologist point of view
Susan Dent, President, International CardiOncology Society (ICOS) Canada, Medical Oncologist, Founder, Canadian Cardiac Oncology Network, Canada

Panel Discussion: All Speakers and Moderators

17:40 WRAP UP AND END OF CONFERENCE
Daniel J. Lenihan and Boaz Mendzelevski

About DIA
DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators, and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for exchange of knowledge and has the interdisciplinary experience to prepare for future developments.

The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.

DIA is an independent, non-profit organisation headquartered in Washington, DC, USA with the European office in Basel, Switzerland, and additional regional offices in Horsham, Pennsylvania, USA; Tokyo, Japan; Mumbai, India; and Beijing, China.

For more information, visit www.diahome.org or call DIA Europe +41 61 225 51 51.
REGISTRATION FORM
Joint DIA/ICOS Conference on Cardiac Toxicity Resulting From Cancer Chemotherapy
9-10 October 2014 | Dorint Hotel Don Giovanni, Prague, Czech Republic

FEES

<table>
<thead>
<tr>
<th>Industry</th>
<th>Academy/Charitable/Government/Non-profit (Full-time)</th>
<th>Joint DIA now to qualify for the member rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member*</td>
<td>€ 1'400.00</td>
<td>€ 150.00</td>
</tr>
<tr>
<td>Non-Member*</td>
<td>€ 1'530.00</td>
<td></td>
</tr>
<tr>
<td>€ 700.00</td>
<td>€ 830.00</td>
<td></td>
</tr>
</tbody>
</table>

* All fees will be subject to the local Czech VAT at 21%

TOTAL AMOUNT DUE: _______________________

ATTENDEE DETAILS

Please complete in block capital letters or attach the attendee’s business card here.

- ☑ Prof
- ☑ Dr
- ☑ Ms
- ☑ Mr

Last Name
First Name
Company
Job Title
Address
Postal Code
City
Country
Telephone
Fax
Email*

*(Required for confirmation)

DIA reserves the right to include your name and affiliation on the attendee list.

PAYMENT METHODS

- ☑ Please charge my
  - ☑ VISA
  - ☑ MC
  - ☑ AMEX

Card N°
Exp. Date
Cardholder’s Name

- ☑ Bank transfers: When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the bank transfer. Payments in EURO should be addressed to “Account Holder: DIA.” Please include your name, company, Event ID #14108 as well as the invoice number to ensure correct allocation of your payment.

Payments must be net of all charges and bank charges must be borne by the payer. If you have not received your confirmation within five working days, please contact DIA Europe.

By signing below, I confirm that I agree with DIA Europe’s Terms and Conditions of booking. These are available from the office or on http://www.diahome.org/EUTerms

Date Signature

CANCELLATION POLICY

All cancellations must be made in writing and be received at the DIA Europe office five working days prior to the event start date. Cancellations are subject to an administrative fee:

- Industry (Member/Non-member) € 200.00
- Academy/Charitable/Government/Non-profit (Full-time) (Member/Non-member) € 100.00
- Tutorial cancellation € 50.00

If you do not cancel five working days prior to the event start date and do not attend, you will be responsible for the full registration fee. DIA Europe reserves the right to alter the venue and dates if necessary. If an event is cancelled or postponed, DIA Europe is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for canceling their own hotel and travel reservations.

TRANSFER POLICY

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA Europe office of any such substitutions as soon as possible.

PHOTOGRAPHY POLICY

By attending the event, you give permission for images of you, captured during the conference through video, photo, and/or digital camera, to be used by DIA Europe in promotional materials, publications, and website and waive any and all rights including but not limited to compensation or ownership.

The DIA Europe Customer Services Team will be pleased to assist you with your registration from Monday to Friday between 08:00 and 17:00 CET.

Email diaeurope@diaeurope.org Tel. +41 61 225 51 51 Fax +41 61 225 51 52 Web www.diaeurope.org Mail DIA Europe, Küchengasse 16, 4051 Basel, Switzerland

© DIA 2014